Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis.

نویسندگان

  • Kazuyoshi Imaizumi
  • Mihoko Sugishita
  • Miho Usui
  • Tsutomu Kawabe
  • Naozumi Hashimoto
  • Yoshinori Hasegawa
چکیده

Two patients with rheumatoid arthritis (RA) that developed serious infectious complications following anti-TNFalpha therapy (infliximab) are reported. Patient 1 developed tuberculosis with high fever, refractory diarrhea and mediastinal lymphadenopathy. Trans-bronchial needle biopsy was useful to confirm the diagnosis. Patient 2 showed sudden onset of dyspnea with diffuse bilateral lung infiltration caused by pneumocystis jiroveci pneumonia and the diagnosis was confirmed by broncho-alveolar lavage. Physicians should be alerted to infectious complications with atypical presentation and rapid progression in infliximab-treated patients. Invasive diagnostic procedures including fiber-optic bronchoscopy may be necessary early in the course for such cases.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Infliximab therapy does not modify MMP-2 and MMP-9 serum concentrations in chronic arthritis.

OBJECTIVE Matrix metalloprotease-2 (MMP-2) and matrix metalloprotease-9 (MMP-9) play a key role in tissue remodelling after processes such as joint destruction in rheumatoid arthritis. Their expression may reflect the disease activity and they could therefore represent a useful marker to assess the efficacy of therapy. In this study MMP-2 and MMP-9 serum were evaluated in patients with chronic ...

متن کامل

How does infliximab work in rheumatoid arthritis?

Since the initial characterization of tumor necrosis factor alpha (TNFalpha), it has become clear that TNFalpha has diverse biologic activity. The realization that TNFalpha plays a role in rheumatoid arthritis (RA) has led to the development of anti-TNF agents for the treatment of RA. Infliximab, a chimeric monoclonal antibody that specifically, and with high affinity, binds to TNFalpha and neu...

متن کامل

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

OBJECTIVE To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab (anti-tumor necrosis factor alpha [anti-TNFalpha] monoclonal antibody) with those of MTX treatment alone in patients with rheumatoid arthritis (RA) of < or =3 years' duration. METHODS RA patients were eligible if they had active disease and no prior treatment with MTX or a TNFalpha inhibitor. One ...

متن کامل

Infliximab treatment for rheumatic disease: clinical and radiological efficacy.

Infliximab is a chimeric anti-tumour necrosis factor alpha (TNFalpha) monoclonal antibody with high affinity and binding specificity for human TNFalpha. Results from several well designed, controlled clinical trials show repeated infusions of infliximab with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of infliximab an...

متن کامل

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register

BACKGROUND Anti-tumour necrosis factor (TNF)alpha treatments improve outcome in severe rheumatoid arthritis (RA) and are efficacious in psoriasis and psoriatic arthritis. However recent case reports describe psoriasis occurring as an adverse event in patients with RA receiving anti-TNFalpha therapy. OBJECTIVES We aimed to determine whether the incidence rate of psoriasis was higher in patient...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Internal medicine

دوره 45 10  شماره 

صفحات  -

تاریخ انتشار 2006